Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256799 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
A Phase 4 study of Cystic Fibrosis, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT03256799: Completed Phase 4 study of Cystic Fibrosis, sponsored by University of Alabama at Birmingham.
NCT03256799 is a Phase 4 study of Cystic Fibrosis that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03256799, a Phase 4 study of Cystic Fibrosis, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
Primary Outcome
change in lung function as measured by spirometry
Conditions Studied
Interventions
- DRUG Ivacaftor/Ataluren
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2018-02-16 |
| Phase | Phase 4 |
What the finished NCT03256799 record still lists
NCT03256799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ivacaftor/Ataluren is the first listed.
NCT03256799 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03256799 about?
NCT03256799 is a clinical study titled "Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations". The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
What is the current status of trial NCT03256799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2017-03-17. Estimated completion is 2018-02-16.
What conditions does trial NCT03256799 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03256799?
The interventions under investigation include: Ivacaftor/Ataluren (DRUG).
Who is sponsoring clinical trial NCT03256799?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03256799 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03256799's enrollment target sits among peer trials
1 170th of 169 the lowest of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI